Modern GLP-1 medicines have transformed obesity treatment, but many people are uncomfortable giving themselves regular injections.
Others face problems with cost, storage, or limited drug supply. Scientists have been searching for an easier option, and a new clinical trial suggests that an oral medicine may provide a promising alternative.
Researchers reported in Nature Medicine that a new drug called aleniglipron helped adults with obesity or overweight lose up to 12% of their body weight after 36 weeks. The international research included scientists from several institutions, including Northwestern University, where endocrinologist Dr. Robert Kushner contributed to the study.
GLP-1 medicines work by copying a hormone naturally released after eating. This hormone tells the brain that the body is full, reduces hunger, slows digestion, and improves insulin release. Together, these effects help people eat less and improve blood sugar control.
Current GLP-1 treatments such as semaglutide are peptides that must be injected. Aleniglipron is different because it is a chemically produced small-molecule medicine taken by mouth once each day. Because it is manufactured differently, it may eventually be easier to produce on a larger scale and more convenient for patients.
The phase II study involved 230 adults treated at 38 U.S. medical centers. Participants were randomly assigned to receive placebo or one of three aleniglipron doses. Neither the volunteers nor the researchers knew who received the active medicine until the study ended, helping reduce bias. Treatment continued for 36 weeks with gradual dose increases.
Weight loss improved as the dose increased. Average reductions reached 9.0%, 10.7%, and 12.1% across the three treatment groups, while the placebo group experienced almost no change. These results are considered clinically meaningful because losing even 5% to 10% of body weight can improve blood pressure, blood sugar, and other obesity-related health problems.
Digestive side effects were the most common, but they were usually mild or moderate and became less frequent over time. Around one in ten participants stopped treatment. Importantly, researchers did not identify new safety concerns or evidence of liver damage.
Although these findings are encouraging, the study does not prove that aleniglipron is ready for widespread use. Phase III clinical trials involving many more participants are still needed to confirm safety, compare the drug with existing treatments, and determine whether the benefits continue over several years.
If those studies are successful, an effective oral GLP-1 medicine could make obesity treatment more convenient, expand patient access, and reduce reliance on injectable medications. The research represents an important advance but should be viewed as a promising step rather than a final answer.
If you care about weight loss, please read studies about orange that could help obesity, and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about ginger’s journey in weight management ,and green tea: a cup of weight loss.
Source: Northwestern University.
